Hypo-Fractionated Radiotherapy in Breast Cancer
NCT03669497 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33
Last updated 2023-12-22
Summary
This is a prospective interventional phase I/II study which will be done at Tata Medical Centre, Kolkata. Total 30 eligible female patients, ≥18 years of age, with locally advance invasive carcinoma of breast, not amenable to curative surgery of metastatic breast cancer, planned for palliative loco regional radiotherapy will be enrolled in the study amongst which patients with left sided breast cancer (at least 10) will be recruited to study the feasibility of voluntary breath hold technique for heart sparing. Once consented, all patients will have regional baseline PET-CT scan of breast and tissue biopsy along with blood sampling done before studying radiotherapy. Planning Ct scan will then be taken, with standard planning CT scan for right breast cancers with implementation voluntary breath hold technique for the left breast disease. All patients will be treated with hypo-fractionated radiotherapy with schedule of 26Gy on 5 Fractions over 1 week with 6Gy simultaneously integrated boost with incorporation of breath hold technique for left breast disease. All patients will be assessed weekly during course of radiotherapy. The toxicity will be assessed using CTCAE version 4 and LENT SOMA toxicity criteria and the impact of the hypo-fractionated breast radiotherapy schedule on quality of life in advanced incurable breast cancer patients using FACT B scores PHQ4 questionnaire will also be assessed during treatment and follow-ups tissue bio0psy will be taken after 2 hours of completion of 1 st and last fraction of radiotherapy and biobanked for future radiobiological tests. Response evaluation will be done clinically and by regional PET CT scan using PERSIST criteria in 3 months after completion of radiotherapy. After completion of treatment, patient will initially be followed up every month for 1 st three months thereby 3 monthly for 2 years and 6 monthly for next 3 years.
Conditions
Interventions
- RADIATION
-
Hypo fractionated whole breast radiotherapy
Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
Sponsors & Collaborators
-
Tata Medical Center
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-02
- Primary Completion
- 2020-12-02
- Completion
- 2021-09-06
Countries
- India
Study Locations
More Related Trials
-
DP303c in Patients With HER2-positive Advanced Breast Cancer
NCT05901935 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
NCT03691493 ·Status: COMPLETED ·Phase: PHASE2
-
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
NCT03273595 ·Status: UNKNOWN ·Phase: PHASE2
-
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
NCT03109080 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
NCT06475443 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06519370 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
NCT03818685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
NCT00444587 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
NCT00951665 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)
NCT05359120 ·Status: UNKNOWN
-
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03853707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
NCT01097642 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT04683679 ·Status: RECRUITING ·Phase: PHASE2
-
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
NCT03910712 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05534438 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
NCT06975644 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
NCT06533722 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
NCT06682195 ·Status: RECRUITING ·Phase: PHASE2
-
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
NCT06489821 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer
NCT01159405 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
NCT01363986 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
NCT00440622 ·Status: TERMINATED ·Phase: PHASE3
-
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
NCT00002755 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
NCT01290718 ·Status: TERMINATED ·Phase: PHASE2